Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells 801 Shares

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 801 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $124.91, for a total transaction of $100,052.91. Following the completion of the transaction, the insider directly owned 21,099 shares of the company’s stock, valued at $2,635,476.09. The trade was a 3.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54.
• On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The shares were sold at an average price of $99.28, for a total transaction of $339,339.04.

Billiontoone Trading Up 2.5%

NASDAQ BLLN opened at $123.40 on Tuesday. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $138.70. The company has a fifty day simple moving average of $97.00 and a two-hundred day simple moving average of $88.08. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $95.81 million. During the same period last year, the firm earned ($0.39) earnings per share. Billiontoone’s quarterly revenue was up 83.8% compared to the same quarter last year. On average, equities research analysts expect that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BLLN. Guggenheim started coverage on Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective on the stock. BTIG Research dropped their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BLLN. Rossby Financial LCC acquired a new position in Billiontoone in the fourth quarter valued at approximately $25,000. Wells Fargo & Company MN acquired a new stake in shares of Billiontoone during the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC purchased a new position in shares of Billiontoone during the 4th quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Billiontoone in the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC purchased a new stake in Billiontoone during the fourth quarter worth $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.